Common use of Additional Issuances Clause in Contracts

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described in the Reports or on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(dSCHEDULE 5(D). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(dSCHEDULE 5(D).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock ’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d)) or as described in the Reports. The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day immediately preceding and following the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or other equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock and all other equity of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or its Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is and the components thereof are set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Initial Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d)) . The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d)) .

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Initial Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the subsidiaries of the Company except as described on Schedule 5(d). The Common Stock stock of the Company Common Stock on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described in the Reports or on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day business day preceding the Closing Date is and the components thereof are set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s or any of its Subsidiaries’ Common Stock or other equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock and all other equity of the Company and its Subsidiaries on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock Ordinary Shares or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock Ordinary Shares or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock Ordinary Shares of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described in the Reports or on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the subsidiaries of the Company except as described on Schedule 5(d). The Common Stock common stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding immediately following the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or -------------------- preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or its Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or its Subsidiaries or other equity interest in the Company except as described on in the public filings and Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d)) or as described in the Reports. The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding immediately following the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock ’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d4(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d4(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock ’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d)) or as described in the Reports. The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day immediately preceding and following the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s Common Stock or other equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock and all other equity of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock common stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock ’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day trading day preceding the Closing Date is set forth on Schedule 5(d).. 5

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's ’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company or Subsidiaries or other equity interest in the Company except as described on Schedule 5(d4(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day preceding the Closing Date is set forth on Schedule 5(d4(d).